Trial Profile

A Phase IIa Open Label Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 Administered by Nebulization in Subjects With Mild to Moderate Cystic Fibrosis and Non CF Bronchiectasis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carbon dioxide/perflubron (Primary)
Indications Cystic fibrosis
Focus Adverse reactions
Sponsors SolAeroMed

Most Recent Events

11 Jun 2021 Planned End Date changed from 1 Aug 2020 to 1 Aug 2022.
11 Jun 2021 Planned primary completion date changed from 1 Apr 2020 to 1 Feb 2022.
20 May 2020 Interim results presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com